Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- La Jolla Is Too Much of a Gamble Right Now
- VFC submits: A comment from a reader:Do you think LJPC's Lupus drug may have some sort of miracle afterlife (similar to Titan (TTNP.PK))? I have made efforts to reach the company to no avail, but the trading action on this "dead" stock has been very unusual the last two...
- External links 2009-09-02
- Titan Pharma Investors' Wait Will Be Well Worth It
- VFC submits: Shares of Titan Pharmaceuticals (TTNP.PK) continue to trade in a somewhat flat trading range as investors eagerly await the anticipated fourth quarter launch of Fanapt - a schizophrenia drug produced by Vanda Pharmaceuticals VNDA - of which Titan will receive between 8-10% in royalties. It's been long...
- External links 2009-09-30
- Keryx Pharma Could Turn into a Real Winner Down the Road
- VFC submits: In an early Tuesday press release, Keryx Pharmaceuticals KERX announced positive information regarding the continued "impressive" efficacy of its treatment for Advanced Metastatic Renal Cell Carcinoma, Perifosine. This news followed the recent announcement of positive Phase II trials for Zerenex, the company's treatment for developing kidney disease.While...
- External links 2009-09-30
- BioDelivery Sciences Requires Strong Investor Confidence
- VFC submits: Shares of BioDelivery Sciences BDSI put a halt to the stock's current downtrend on Monday, closing at $4.79 after closing last week at $4.24. Early trading on Tuesday saw the stock trading relatively flat, aside from an early morning when BDSI spiked to nearly five dollars.Monday's spike,...
- External links 2009-09-30
- The Worst Is Way Behind Titan Pharma
- VFC submits: [Update below] I've discussed Titan Pharmaceuticals (TTNP.PK) in great depth here over the past eight months or so, but a rundown of where I think this stock could go - based on the potential of Fanapt sales and Titan's 8-10% royalty rate - is as follows: by...
- External links 2009-10-02
- Keryx Pharmaceuticals: Time to Buy Back In
- VFC submits: When shares of Keryx Biopharmaceuticals KERX spiked to over three dollars on Tuesday after the company issued a press release regarding the continued "impressive" efficacy of its treatment for Advanced Metastatic Renal Cell Carcinoma, Perifosine, I stated that it was a good time to take some profits...
- External links 2009-10-04
- Access Pharma's Prospects Look Good Even Without a Buyout
- VFC submits: An email from 'Marty' regarding Access Pharmaceuticals (ACCP.OB):What's your take on Access Pharma?...I'm hearing lots of takeover rumors but that's not enough to warrant a strong position. What are its prospects as a stand-alone and what are your thoughts about a possible buy out? by VFC's Stock...
- External links 2009-10-04
- Cel-Sci May Be in for a Bumpy Ride This Week
- VFC submits: It looks like the writing staff at BioMedReports.com, most notably M. E. Garza, must be getting under Adam Feuerstein's skin because he's decided to enact a personal vendetta with the website. The thing is, it makes Adam and his puppetmasters at the The Street.com looks pretty bad...
- External links 2009-10-04
- Investors Should Ignore the Hoopla Around Cel Sci
- VFC submits: Shares of Cel Sci CVM traded down during pre-market trading on Tuesday after The Street.com published yet another article bashing the company and the potential of its pipeline. Undoubtedly some shareholders are going to be shaken out of the stock by the antics of Feuerstein, but I...
- External links 2009-10-07
- Time to Gain a Foothold in Transdel Pharma
- VFC submits: Shares of Transdel Pharmaceuticals (TDLP.OB) traded up to as high as four dollars during early trading on Tuesday after the company announced positive Phase III trial results for its lead topical pain drug Ketotransdel. The trial, according to the press release, "evaluated the efficacy and safety of...
- External links 2009-10-07
- BioDelivery's Products Attract Growing Interest
- VFC submits: Shares of BioDelivery Sciences BDSI broke above the $5 dollar barrier for the first time in a little while after a Tuesday morning press release announced that the company has received a $1.3 million grant from the Walter Reed Army Institute of Research. The grant, according to...
- External links 2009-10-07
- Remaining Grounded Through the Unethical Attacks on Cel Sci
- VFC submits: [Update below] Shares of Cel Sci Corp CVM were on the rebound during early trading on Wednesday after the effects of some unfounded attacks on the company by Adam Feuerstein and The Street.com look to have finally wore off. by VFC's Stock House
- External links 2009-10-08
- Cel Sci: Job Listings Are a Good Sign
- VFC submits: What's left to say about Cel Sci Corp. CVM? That company and its stock have received a heck of a lot of press over the past couple of weeks and I maintain my opinion that - in my opinion - the stock will pay off based on...
- External links 2009-10-08
- Continuing to Accumulate Peregrine Pharma at Current Levels
- VFC submits: On Monday Peregrine Pharmaceuticals issued a press release announcing Positive Results From the company's Phase II Bavituximab Lung Cancer Trial. A full copy of the press release is here. The PR had little, if any, influence on the stock price. I started accumulating shares of this...
- External links 2009-10-08
- Have to Like the Risk/Reward in Antigenics Stock
- VFC submits: Nothing has changed with the potential of Antigenics AGEN and its stock. If anything, the longer it trades for a price of near two dollars, the better buy it becomes because the closer news is to being released.Investors have heard nothing that would lead us to believe...
- External links 2009-09-27
- Taking Advantage of the BioDelivery Dip
- VFC submits: Shares of BioDelivery Sciences BDSI ended the trading week last week at $4.24, a nearly 50% price cut from the stock's 52-week high of over $8. I know that many investors start feeling the panic set in when a stock that they thought was a winner, such...
- External links 2009-09-27
- Short Interest in BioDelivery Sciences Is Good News
- VFC submits: A comment from a reader:I am considering your pick of BioDelivery Sciences BDSI and have done my own Due Diligence. What in your opinion explains the 12.39% current short interest? Also, what are the potential sales projections to market? by VFC's Stock House
- External links 2009-09-02
- Antigenics' Current Price is Irresistible
- VFC submits: I've spent plenty of time discussing the potential of Antigenics AGEN as one of a few candidates to become the next Dendreon DNDN and I once again could not refuse adding to my position for just under $2.As I've also mentioned before, AGEN is one of only...
- External links 2009-09-06
- Epicept Investors Still Waiting on News of a Partner
- VFC submits: Shares of Epicept EPCT have logged quite the volatile week of trading after a price spike carried shares to near the $1 mark before immediately retreating to the eighty cent level.A press release was issued on Thursday by the company highlighting some recent positive recognition for Ceplene,...
- External links 2009-09-06
- Cell Therapeutics Looks Good, Antigenics Looks Better
- VFC submits: In response to a number of requests that I've received via email or comments asking for 'VFC's Take' on numerous stocks that readers have found, I'll do my best to address as many as I can, as long as everyone takes a few things into account while...
- External links 2009-09-08
- << Previous
- page 1 of 7
- Next >>
Refining Tags
- Biotech (75 results)
- Healthcare (40 results)
- Antigenics Inc. (20 results)
- BioDelivery Sciences International Inc. (18 results)
- CEL-SCI Corp. (11 results)
- Retail (8 results)
- Media (8 results)
- EpiCept Corp. (6 results)
- Vanda Pharmaceuticals Inc. (6 results)
- Capstone Turbine (5 results)
- Energy (5 results)
- Insmed Inc. (5 results)
- Materials & Industrials (4 results)
- Keryx Biopharmaceuticals Inc. (4 results)
- US Market (4 results)
- Sirius Satellite Radio Inc. (4 results)
- Sirius (4 results)
- Financial (3 results)
- Marvel Entertainment Inc. (3 results)
- Capstone Turbine Corp. (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
